JP7211974B2 - 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 - Google Patents

増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 Download PDF

Info

Publication number
JP7211974B2
JP7211974B2 JP2019562349A JP2019562349A JP7211974B2 JP 7211974 B2 JP7211974 B2 JP 7211974B2 JP 2019562349 A JP2019562349 A JP 2019562349A JP 2019562349 A JP2019562349 A JP 2019562349A JP 7211974 B2 JP7211974 B2 JP 7211974B2
Authority
JP
Japan
Prior art keywords
gel
gel composition
water
drug
ascorbyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019562349A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519635A5 (https=
JP2020519635A (ja
Inventor
デル ポル， デレク ジー． ヴァン
ドミニク ジェイ． ブラシオリ，
グレゴリー ティー． ズゲイツ，
Original Assignee
アリヴィオ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリヴィオ セラピューティクス， インコーポレイテッド filed Critical アリヴィオ セラピューティクス， インコーポレイテッド
Publication of JP2020519635A publication Critical patent/JP2020519635A/ja
Publication of JP2020519635A5 publication Critical patent/JP2020519635A5/ja
Priority to JP2022080798A priority Critical patent/JP2022103299A/ja
Application granted granted Critical
Publication of JP7211974B2 publication Critical patent/JP7211974B2/ja
Priority to JP2023014533A priority patent/JP2023041861A/ja
Priority to JP2023173522A priority patent/JP2023168587A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019562349A 2017-05-08 2018-05-08 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 Active JP7211974B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022080798A JP2022103299A (ja) 2017-05-08 2022-05-17 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤
JP2023014533A JP2023041861A (ja) 2017-05-08 2023-02-02 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤
JP2023173522A JP2023168587A (ja) 2017-05-08 2023-10-05 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502872P 2017-05-08 2017-05-08
US62/502,872 2017-05-08
PCT/US2018/031654 WO2018208822A1 (en) 2017-05-08 2018-05-08 Formulation of nanostructured gels for increased agent loading and adhesion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022080798A Division JP2022103299A (ja) 2017-05-08 2022-05-17 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤

Publications (3)

Publication Number Publication Date
JP2020519635A JP2020519635A (ja) 2020-07-02
JP2020519635A5 JP2020519635A5 (https=) 2021-05-27
JP7211974B2 true JP7211974B2 (ja) 2023-01-24

Family

ID=62223333

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019562349A Active JP7211974B2 (ja) 2017-05-08 2018-05-08 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤
JP2022080798A Pending JP2022103299A (ja) 2017-05-08 2022-05-17 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤
JP2023014533A Pending JP2023041861A (ja) 2017-05-08 2023-02-02 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤
JP2023173522A Pending JP2023168587A (ja) 2017-05-08 2023-10-05 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022080798A Pending JP2022103299A (ja) 2017-05-08 2022-05-17 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤
JP2023014533A Pending JP2023041861A (ja) 2017-05-08 2023-02-02 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤
JP2023173522A Pending JP2023168587A (ja) 2017-05-08 2023-10-05 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤

Country Status (6)

Country Link
US (2) US10881745B2 (https=)
EP (1) EP3621594A1 (https=)
JP (4) JP7211974B2 (https=)
AU (2) AU2018266131B2 (https=)
CA (1) CA3061480A1 (https=)
WO (1) WO2018208822A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3136635A1 (en) * 2019-04-11 2020-10-15 Convatec Technologies Inc. Superporous hydrogels, methods of making the same, and articles incorporating the same
CN111781128B (zh) * 2020-06-15 2023-07-07 迪瑞医疗科技股份有限公司 一种尿分析仪用鞘液及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009525760A (ja) 2006-02-10 2009-07-16 デユポン・テイト・アンド・ライル・バイオ・プロダクツ・カンパニー・エルエルシー 再生ベースの生分解性１，３−プロパンジオールを含む生分解性組成物
JP2013523694A (ja) 2010-04-01 2013-06-17 ファーマネスト・エイビイ 局所麻酔薬の生体接着性組成物
JP2013540757A (ja) 2010-09-24 2013-11-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド カプセル化された作用物質の放出を制御する能力を有するナノ構造ゲル
WO2017062818A1 (en) 2015-10-08 2017-04-13 The Brigham And Women's Hospital, Inc. Stabilized assembled nanostructures for delivery of encapsulated agents
JP2019514957A (ja) 2016-05-06 2019-06-06 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 軟骨へのカプセル化薬剤の制御送達のための二成分型自己集合ゲル

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2417494A1 (fr) 1978-02-16 1979-09-14 Bottu Nouvelles compositions analgesiques et antipyretiques contenant un derive de paracetamol
AU653026B2 (en) 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
GB9403857D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
JP3439481B2 (ja) * 1995-11-15 2003-08-25 生化学工業株式会社 光架橋ヒアルロン酸ゲルおよびその製造法
CA2212300A1 (en) 1997-08-04 1999-02-04 Abdellatif Chenite In vitro or in vivo gelfying chitosan and therapeutic uses thereof
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
FR2794998B1 (fr) 1999-06-21 2001-07-27 Oreal Organogels et leurs utilisations notamment cosmetiques
WO2003006043A1 (en) 2001-07-10 2003-01-23 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
US20050084470A1 (en) 2003-10-15 2005-04-21 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care and cleansing compositions containing oil seed product
CA2544814C (en) 2003-11-12 2013-05-14 Applied Nanosystems B.V. Non-symmetrical gelling agent
ES2380340T3 (es) 2003-12-05 2012-05-10 Northwestern University Anfífilos peptídicos auto-ensamblantes y métodos relacionados para la administración de factores de crecimiento
US7410950B2 (en) * 2004-04-01 2008-08-12 Board Of Regents, The University Of Texas System Peptides of CaV2.2 that inhibit pain
EP1750671B1 (en) 2004-06-03 2008-10-15 Bracco Research S.A. Liposomal assembly for therapeutic and/or diagnostic use
FR2871701B1 (fr) 2004-06-21 2006-09-22 Centre Nat Rech Scient Cnrse Biomateriaux bioactifs pour le relarguage controle de principes actifs
US7854943B2 (en) * 2004-06-24 2010-12-21 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
EP1800694A1 (en) 2005-12-23 2007-06-27 Applied NanoSystems B.V. Controlled release gels
EP1991515A4 (en) * 2006-02-10 2013-03-06 Dupont Tate & Lyle Bio Products Company Llc BIOLOGICAL SOURCE AND ITS CONJUGATES AS NATURAL AND NON-BREATHING SOLVENTS FOR BIOMASS EXTRACTS, SCENT CONCENTRATES AND OILS
US8968784B2 (en) 2006-05-22 2015-03-03 Research Foundation Of The City University Of New York Method for preparing hydro/organo gelators from disaccharide sugars by biocatalysis and their use in enzyme-triggered drug delivery
US20080021068A1 (en) * 2006-07-24 2008-01-24 Akorn, Inc. Aqueous gel formulation and method for inducing topical anesthesia
JP5358574B2 (ja) * 2007-08-17 2013-12-04 アルション セラピューティクス， インコーポレイテッド 高濃度の局所麻酔薬調合物
WO2009029543A1 (en) 2007-08-24 2009-03-05 Aegis Therapeutics, Llc Controlled release formulations
US20090263489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
WO2010033726A2 (en) 2008-09-17 2010-03-25 The Brigham And Women's Hospital, Inc. Drug delivery composition comprising a self-assembled gelator
JP5724108B2 (ja) * 2009-04-22 2015-05-27 メドスキン ソリューションズ ドクター ズベラック アーゲーＭｅｄＳｋｉｎ Ｓｏｌｕｔｉｏｎｓ Ｄｒ．Ｓｕｗｅｌａｃｋ ＡＧ 凍結乾燥組成物
AU2015200633A1 (en) * 2009-05-04 2015-02-26 Zars Pharma, Inc. Methods for treating pains associated with neuroma, nerve entrapment, and other conditions
CA2770490C (en) * 2009-08-11 2024-04-16 The Johns Hopkins University Compositions and methods for implantation of processed adipose tissue and processed adipose tissue products
CN102834096A (zh) * 2010-01-14 2012-12-19 卢福研究公司 用于疼痛控制的固态成型局部麻醉制剂
EP2361640A1 (en) 2010-02-25 2011-08-31 Université de Liège Cell cultivation in chitosan alginate hydrogel beads
GB201020193D0 (en) 2010-11-29 2011-01-12 Biotec Pharmacon Asa Glucan compositions
ES2390428B1 (es) * 2011-04-15 2013-10-01 Universidad De Almería Preparado de bacterias probióticas para su administración oral a peces cultivados basado en la encapsulación en hidrogeles de alginato.
CN104582826B (zh) 2012-06-25 2018-06-05 日产化学工业株式会社 分散液及水凝胶形成方法
EP2968109A2 (en) 2012-09-14 2016-01-20 Cipla Limited Topical pharmaceutical composition comprising tenofovir, an antibacterial agent and, optonally ciclopirox
EP2928513B1 (en) 2012-12-07 2018-06-06 Kansas State University Research Foundation Peptide-albumin hydrogel properties and its applications
EP2968135A4 (en) 2013-03-14 2016-10-26 Massachusetts Inst Technology INJECTABLE, MULTILAYER, SELF-COMPOSITE PEPTIDE RUBBER HYDROGELS FOR LONG-TERM AND DELAYED RELEASE OF HUMAN ANTIBODIES
US9789073B2 (en) * 2013-03-14 2017-10-17 Pathak Holdings, Llc Compositions, methods and devices for local drug delivery
US20150297731A1 (en) * 2014-04-21 2015-10-22 National Yang-Ming University Thermosensitive injectable glaucoma drug carrier gel and the fabricating method thereof
US9452178B1 (en) * 2014-10-22 2016-09-27 SatisPharma, LLC Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations
US20170360912A1 (en) * 2014-12-17 2017-12-21 Socovar, L.P. Chitosan-based hydrogel and applications thereof.
EP4279064A3 (en) * 2015-05-12 2024-02-28 Incept, LLC Drug delivery from hydrogels
US20170319500A1 (en) 2016-05-06 2017-11-09 The Brigham And Women's Hospital, Inc. Self-assembled gels for controlled delivery of biologics and labile agents
US20180050055A1 (en) * 2016-08-16 2018-02-22 Hafiz Ahmed Exploiting nutrient deprivation for modulation of glycosylation - research diagnostic, therapeutic, and biotechnology applications
EP3335695B1 (en) * 2016-12-15 2020-02-05 UPM-Kymmene Corporation A method for freeze-drying hydrogel comprising nanofibrillar cellulose, a freeze-dried medical hydrogel comprising nanofibrillar cellulose, and a hydrogel comprising nanofibrillar cellulose

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009525760A (ja) 2006-02-10 2009-07-16 デユポン・テイト・アンド・ライル・バイオ・プロダクツ・カンパニー・エルエルシー 再生ベースの生分解性１，３−プロパンジオールを含む生分解性組成物
JP2013523694A (ja) 2010-04-01 2013-06-17 ファーマネスト・エイビイ 局所麻酔薬の生体接着性組成物
JP2013540757A (ja) 2010-09-24 2013-11-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド カプセル化された作用物質の放出を制御する能力を有するナノ構造ゲル
WO2017062818A1 (en) 2015-10-08 2017-04-13 The Brigham And Women's Hospital, Inc. Stabilized assembled nanostructures for delivery of encapsulated agents
JP2019514957A (ja) 2016-05-06 2019-06-06 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 軟骨へのカプセル化薬剤の制御送達のための二成分型自己集合ゲル

Also Published As

Publication number Publication date
JP2023041861A (ja) 2023-03-24
US20210196836A1 (en) 2021-07-01
JP2023168587A (ja) 2023-11-24
JP2020519635A (ja) 2020-07-02
AU2018266131B2 (en) 2021-07-29
AU2018266131A1 (en) 2020-01-02
US10881745B2 (en) 2021-01-05
AU2021240143B2 (en) 2023-10-19
AU2021240143A1 (en) 2021-10-28
US20180318442A1 (en) 2018-11-08
JP2022103299A (ja) 2022-07-07
CA3061480A1 (en) 2018-11-15
WO2018208822A1 (en) 2018-11-15
EP3621594A1 (en) 2020-03-18

Similar Documents

Publication Publication Date Title
AU2016335846B2 (en) Stabilized assembled nanostructures for delivery of encapsulated agents
CA3062885C (en) Self-assembled gels for controlled delivery of biologics and labile agents
US20230364014A1 (en) Self-assembled gels for controlled delivery of biologics and methods of making thereof
JP2023168587A (ja) 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤
WO2012122493A1 (en) Lipid based clopidogrel compositions, methods, and uses
CN102227210B (zh) 亲脂性物质溶液,特别是药物溶液
HK1159493B (en) Solution of lipophilic substances, especially medicinal solutions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210414

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220927

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230112

R150 Certificate of patent or registration of utility model

Ref document number: 7211974

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150